Bayer has won another major EU approval in oncology after the European Commission back Xofigo for use in prostate cancer. The marketing authorisation covers the use of an injectable version of the company’s radiotherapy Xofigo (radium Ra 223 dichloride) for the treatment of men with castration-resistant prostate cancer (CRPC) who also have symptomatic bone metastases and no known visceral metastases. The decision comes just over two months after Bayer received approval for fellow oncology drug Stivarga (regorafenib) for use in the treatment of colorectal cancer.
Help employers find you! Check out all the jobs and post your resume.
